Physician profile
Jon W Beasley
NPI 1386671774
$16,727.21
in general payments reported to CMS, 2019-2025
45 companies · $15.75 in 2025
The $15.75 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,104 · 2020: $3,194 · 2021: $3,277 · 2022: $3,504 · 2023: $3,141 · 2024: $491 · 2025: $15.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,618 · Education: $29.51.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,618.37 |
| Education | $29.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,860.98 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,789.38 | 2019-2024 | Farxiga, Breztri |
| Pfizer INC. | $1,340.02 | 2019-2025 | |
| Lilly USA, LLC | $1,331.87 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Sanofi-Aventis U.S. LLC | $1,009.76 | 2019-2023 | |
| Amarin Pharma, INC. | $994.27 | 2019-2022 | |
| Amgen INC. | $952.99 | 2019-2024 | Repatha, Otezla, Prolia |
| Abbvie INC. | $903.81 | 2021-2024 | Vraylar, Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $661.49 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $433.95 | 2019-2024 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $400.07 | 2019-2023 | Trintellix |
| Novartis Pharmaceuticals Corporation | $393.14 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $389.67 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $385.11 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $383.28 | 2020-2023 | Jardiance |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Beasley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.